Latigo Biotherapeutics Sets Terms for $272 Million IPO, Backed by NEJM-Published Phase 2 Data for Its Non-Opioid Pain Candidate

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO), a clinical-stage biopharmaceutical company developing oral, selective Nav1.8 inhibitors as non-opioid alternatives for acute and chronic pain, announced terms for its IPO on August 3, 2026. The Thousand Oaks, California-based company plans to raise $272 million by offering 16 million shares at a price range of $16 to $18, implying a fully diluted market value of approximately $1.2 billion at the midpoint. Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities serve as joint bookrunners, with pricing expected during the week of August 3. The offering arrives days after Latigo published its pivotal-quality Phase 2 LTG-001 results in the New England Journal of Medicine.

Phase 2 Data Published in NEJM Outperformed Vicodin and Set an Analgesic Record

The clinical case for Latigo’s IPO rests on a 343-patient, randomized, placebo- and comparator-controlled Phase 2b abdominoplasty trial that met its primary SPID48 endpoint and all key secondary endpoints with high statistical significance. High-dose LTG-001 achieved a SPID48 of 62.1, which Latigo describes as the highest analgesic effect ever reported for any drug tested in the abdominoplasty pain model. That compares with a SPID48 of 40.86 for the opioid comparator hydrocodone/acetaminophen (Vicodin). High-dose LTG-001 also kept 52% of patients opioid-free during treatment versus 22% on placebo, demonstrating meaningful opioid-sparing potential. The NEJM publication marks only the second original research article in that journal reporting clinical results for a novel acute pain drug in the last 15 years. Notably, LTG-001 produced faster onset of pain relief than Vicodin and showed no evidence of addiction liability, the core commercial thesis the company takes into Phase 3.

Nav1.8 Has FDA Precedent But LTG-001 Aims to Go Further Than Journavx

Latigo does not enter a completely blank regulatory landscape. Vertex Pharmaceuticals’ suzetrigine (Journavx) received FDA approval in 2025 as the first Nav1.8 inhibitor, providing a clear development and regulatory precedent for the class. That approval validates both the target and the regulatory pathway, reducing the scientific risk that the first Nav1.8 program would have faced. Latigo, however, differentiates LTG-001 on efficacy: the SPID48 of 62.1 in the high-dose arm exceeds the analgesic signal Journavx showed in its own pivotal trials, a claim the company makes explicitly in its registration statement. Phase 3 plans for LTG-001 include a bunionectomy trial in H2 2026, which is the FDA’s preferred surgical pain model and the one Vertex used to anchor Journavx’s approval, making head-to-head comparability a natural downstream question even without a formal head-to-head trial.

A Three-Asset Pipeline and $272 Million to Fund Phase 3 and Beyond

Beyond LTG-001, Latigo advances LTG-321, a next-generation Nav1.8 inhibitor targeting chronic musculoskeletal pain, beginning with osteoarthritis of the knee. A Phase 2 proof-of-concept trial is underway with topline data expected in H2 2027. An open-label Phase 3 safety trial for LTG-001 is also planned for H2 2026. Earlier-stage programs include LTG-418, a preclinical Nav1.8 inhibitor, and additional discovery work targeting other ion channels involved in pain transmission. Latigo’s investor base includes Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital. The $272 million IPO proceeds fund the LTG-001 Phase 3 bunionectomy trial and open-label safety study, Phase 2 completion for LTG-321, and general corporate purposes. Topline Phase 3 data for LTG-001 in bunionectomy is expected in H2 2027.

Strategic Investment Summary

• IPO Terms: Latigo Biotherapeutics (NASDAQ: LTGO) plans to raise $272 million by offering 16 million shares at $16 to $18, implying a fully diluted market value of approximately $1.2 billion at the midpoint, with pricing expected during the week of August 3, 2026.
• Phase 2 Efficacy: High-dose LTG-001 achieved a SPID48 of 62.1 in a 343-patient abdominoplasty trial versus 40.86 for Vicodin, keeping 52% of patients opioid-free versus 22% on placebo; results were published in the New England Journal of Medicine on July 29, 2026.
• Regulatory Precedent: Vertex’s suzetrigine (Journavx), approved by the FDA in 2025 as the first Nav1.8 inhibitor, validates the target and the regulatory pathway; Latigo claims LTG-001’s SPID48 exceeds Journavx’s pivotal efficacy signal.
• Phase 3 Roadmap: A Phase 3 bunionectomy trial (the FDA’s preferred acute pain surgical model) and an open-label safety trial are planned for H2 2026, with topline results expected H2 2027.
• Pipeline Depth: LTG-321, a Nav1.8 inhibitor for chronic musculoskeletal pain (osteoarthritis), is in Phase 2 with H2 2027 data expected; earlier-stage programs include LTG-418 and additional ion channel discovery work.
• Safety Flags: High-dose LTG-001 was associated with a higher incidence of pyrexia (7% vs. 2%) and presyncope (6% vs. 1%) versus placebo in the Phase 2 trial; regulators and investors should weigh these signals against the strong efficacy profile heading into Phase 3.

Find out more about Latigo Biotherapeutics’ clinical pipeline at the Latigo pipeline page.